Medicine and Dentistry
Atrial Fibrillation
100%
Direct Oral Anticoagulant
80%
Cohort Analysis
50%
General Medicine
50%
Antithrombotic
50%
Observational Study
50%
Vitamin K Antagonist
50%
Systematic Review
50%
Meta-Analysis
50%
Apoplexy
33%
Warfarin
30%
Randomized Controlled Trial
20%
Brain Ischemia
20%
Major Bleeding
20%
Anticoagulation
10%
Bleeding
10%
Cerebral Hemorrhage
10%
Myocardial Infarction
10%
Attributable Risk
8%
Ciclonicate
6%
Base
5%
Clinical Trial
5%
Subgroup Analysis
5%
Gastrointestinal Bleeding
5%
Exclusion Criterion
5%
Primary Outcome
5%
Nursing and Health Professions
Anticoagulant Agent
75%
Atrial Fibrillation
75%
Cohort Analysis
50%
General Practice
50%
Warfarin
29%
Cerebrovascular Accident
28%
Clinical Practice
26%
Meta Analysis
25%
Antivitamin K
25%
Systematic Review
25%
Brain Ischemia
10%
Bleeding
10%
Anticoagulation
9%
Attributable Risk
7%
Vitamin K Group
5%
Scopus
5%
Base
5%
Medline
5%
Pharmacology, Toxicology and Pharmaceutical Science
Atrial Fibrillation
75%
Direct Oral Anticoagulant
55%
Anticoagulant Agent
50%
Cohort Study
50%
Warfarin
30%
Cerebrovascular Accident
28%
Antivitamin K
25%
Observational Study
25%
Randomized Controlled Trial
15%
Brain Ischemia
10%
Bleeding
10%
Vitamin K Group
5%
Clinical Trial
5%
Base
5%